tetano
Editor, Senior Moderator
Infect Drug Resist
. 2021 Jul 12;14:2667-2674.
doi: 10.2147/IDR.S314938. eCollection 2021.
Clinical Efficacy of Corticosteroids in the Early Stages of Deterioration in COVID-19 Pneumonia
Zheng Liu[SUP] #[/SUP][SUP] 1 [/SUP], Fang Shi[SUP] 1 [/SUP], Jun-Xia Liu[SUP] 1 [/SUP], Jia-Qi Liu[SUP] 2 [/SUP], Jing Li[SUP] 1 [/SUP], Qian Wang[SUP] 1 [/SUP], Hui Wang[SUP] 1 [/SUP], Chang-Lan Gao[SUP] 3 [/SUP], Jian-Min Li[SUP] 1 [/SUP], Dong-Fang Zhao[SUP] #[/SUP][SUP] 1 [/SUP]
Affiliations
Abstract
Background: The World Health Organization (WHO) strongly suggests using corticosteroids in patients with severe coronavirus disease 2019 (COVID-19). Similarly, a large randomized controlled clinical trial (RCT) in the UK found that dexamethasone effectively reduced the mortality rate in severe COVID-19 patients. However, the safety profile of corticosteroids has been a controversial area of study.
Case description: A case of a COVID-19 patient is described and the clinical characteristics are observed as the mildly symptomatic patient progresses into a critically ill patient and during their dramatic improvement with corticosteroid therapy in the early stage of the deterioration process with COVID-19 pneumonia.
Conclusion: The most suitable timing and dosage for the use of corticosteroids to maximize its effect during the worsening of COVID-19 pneumonia are discussed. One of the main pathophysiological hypotheses for severe COVID-19 patients is related to cytokine storm and virus load, which can be effectively treated with corticosteroid therapy.
Keywords: COVID-19 pneumonia; clinical characteristics; corticosteroids; cytokine storm.
. 2021 Jul 12;14:2667-2674.
doi: 10.2147/IDR.S314938. eCollection 2021.
Clinical Efficacy of Corticosteroids in the Early Stages of Deterioration in COVID-19 Pneumonia
Zheng Liu[SUP] #[/SUP][SUP] 1 [/SUP], Fang Shi[SUP] 1 [/SUP], Jun-Xia Liu[SUP] 1 [/SUP], Jia-Qi Liu[SUP] 2 [/SUP], Jing Li[SUP] 1 [/SUP], Qian Wang[SUP] 1 [/SUP], Hui Wang[SUP] 1 [/SUP], Chang-Lan Gao[SUP] 3 [/SUP], Jian-Min Li[SUP] 1 [/SUP], Dong-Fang Zhao[SUP] #[/SUP][SUP] 1 [/SUP]
Affiliations
- PMID: 34285519
- PMCID: PMC8285565
- DOI: 10.2147/IDR.S314938
Abstract
Background: The World Health Organization (WHO) strongly suggests using corticosteroids in patients with severe coronavirus disease 2019 (COVID-19). Similarly, a large randomized controlled clinical trial (RCT) in the UK found that dexamethasone effectively reduced the mortality rate in severe COVID-19 patients. However, the safety profile of corticosteroids has been a controversial area of study.
Case description: A case of a COVID-19 patient is described and the clinical characteristics are observed as the mildly symptomatic patient progresses into a critically ill patient and during their dramatic improvement with corticosteroid therapy in the early stage of the deterioration process with COVID-19 pneumonia.
Conclusion: The most suitable timing and dosage for the use of corticosteroids to maximize its effect during the worsening of COVID-19 pneumonia are discussed. One of the main pathophysiological hypotheses for severe COVID-19 patients is related to cytokine storm and virus load, which can be effectively treated with corticosteroid therapy.
Keywords: COVID-19 pneumonia; clinical characteristics; corticosteroids; cytokine storm.